The development of artificial organs must go down as one of the major areas of medical advance in this century. Temporary replacement of heart and lung function has permitted miracles of cardiac surgery; renal dialysis has revolutionised the prognosis in acute and chronic renal failure. The analogy with renal disease points to the areas in which artificial livers are required -temporary replacement of function in acute hepatic failure until regeneration has had time to restore normality, and buying time in chronic liver disease until transplantation can be performed. Why have they been so long in coming?
The 46 52 Earlier enthusiastic research in this field53 was slowed in the 1 970s when it was shown that implanted hepatocytes, alive or dead, and even a cytosolic hepatocyte extract, could also improve survival, perhaps reflecting release of stimulators of regeneration. 54 More recently this approach has again been tried, with studies showing that intraperitoneal injection of microencapsulated hepatocytes improves survival after initiation of galactosamine hepatitis in rats when compared with empty alginate microcapsules. 46 In view of the previous demonstration of the apparent benefit from dead hepatocytes or hepatocyte extracts, it is unfortunate that studies still omit this vital (or non-vital!) control. Critical studies have shown that cultures of microencapsulated hepatocytes ex vivo can release hepatic stimulatory substances capable of improving survival in the rat galactosamine model. 55 For any system using hepatocytes, availability of suitable cells presents a challenge. In 1987, Matsumura et al wrote a clinical report of the use of isolated rabbit cells in an extracorporeal system,56 and recently pig cells, maintained on microcarrier cells in a hollow fibre system have been used to treat patients both in the presence of an acutely failing liver and during a brief anhepatic phase before transplantation.57 58 Thus far the documentation of improvement is brief. For general usage, a source of human cells seems desirable, unless sophisticated genetic modification of animal cells to prevent generation of antigenic proteins can be achieved: still a remote goal. Available normal human hepatocytes are scarce, although cryopreservation should ease this problem, but for the moment some competition between transplant surgeons and the artificial liver seems inevitable. Cultured fetal hepatocytes or immortalised lines from normal adult cells are potential prospects, but any manipulation that maintains hepatocytes as dividing cells gives rise to some disquiet, as does the use of tumour derived cell lines even if they are well differentiated. One recent pilot study reports the use of a well differentiated human tumour derived cell line which maintains the property of contact inhibition, so that cartridges of these cells can be maintained in a perfused system 'at the ready'37; regrettably this cell line is the subject of a US patent.
In recent months, abstracts of reports of clinical usage of artificial liver support systems using hollow fibre and whole perfused human liver as well as animal cells have been published.59 60 A clinical trial of the device using human tumour cells has begun; initial reports have not (yet) confirmed a benefit.61 Review of previous clinical studies in this area emphasises (and it seems to need emphasis) that proving the efficacy of complex interventions in the unpredictable setting of severe acute hepatic failure is difficult. Let us hope that workers are self critical in assessing these interventions, and that institutional ethics committees recognise the importance of establishing the true value of these interventions. Despite these recent reports, artificial livers remain tantalising -theoretically impeccable, but still practically remote. The disappointing outcome of adsorption columns, and the failure to show significant benefit from plasmapheresis, seem to leave a bioartificial liver using extracorporeal or implanted hepatocytes as the most promising prospect. Problems of biocompatibility of the hardware, availability of hepatocytes, and ensuring blood or plasma are exposed adequately to the cells to allow exchange to occur, seem likely to employ innovative researchers for some years yet. 
